Trial Profile
The NEMO Trial (NRAS Melanoma and MEK Inhibitor):A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Binimetinib (Primary) ; Dacarbazine
- Indications Malignant melanoma; Skin cancer
- Focus Registrational; Therapeutic Use
- Acronyms NEMO
- Sponsors Array BioPharma; Novartis; Pfizer
- 05 Nov 2019 Status changed from active, no longer recruiting to completed.
- 30 Aug 2019 Planned End Date changed from 31 Jul 2019 to 1 Sep 2019.
- 05 Jul 2019 This trial has been completed in Greece (on 2019-06-04).